Source comparison
CJC-1295 No DAC & Ipamorelin Dosage Anti-Aging: Protocol Comparison
| Protocol Type | CJC-1295 Dose | Ipamorelin Dose | Frequency | Expected IGF-1 Increase | Receptor Tolerance Risk | Professional Assessment ||—|—|—|—|—|—|| Conservative Starter | 100mcg | 100mcg | Nightly (7 days/week) | 15–25% at 8 weeks | Low. Suitable for i
This comparison does not assign a generated winner or score.
- | Protocol Type | CJC-1295 Dose | Ipamorelin Dose | Frequency | Expected IGF-1 Increase | Receptor Tolerance Risk | Professional Assessment ||—|—|—|—|—|—|| Conservative Starter | 100mcg | 100mcg | Nightly (7 days/week) | 15–25% at 8 weeks | Low. Suitable for initial 4 weeks only | Best for assessing individual response before escalation; insufficient for sustained anti-aging benefits beyond month one || Standard Therapeutic | 200–250mcg | 200–250mcg | 5 nights/week | 40–55% at 12 weeks | Moderate. Cycling required beyond 12 weeks | Optimal balance of efficacy and sustainability; this is the evidence-based baseline for anti-aging protocols || Aggressive High-Dose | 400–500mcg | 400–500mcg | Nightly (7 days/week) | 60–75% at 6 weeks, declining to 25–30% by week 12 | High. Tolerance develops rapidly | Produces early dramatic results that plateau hard; not recommended for protocols longer than 8 weeks || Maintenance Cycling | 200–300mcg | 200–300mcg | 5 nights/week, 4 weeks on / 1 week off